Bristol Myers Squibb nabs iPierian in $175M buyout

| | Health Imaging | Molecular Imaging

Bristol-Myers Squibb now holds the power on a pipeline of neurodegenerative disease therapies after buying San Francisco-based IPierian for $175 million. iPierian is reportedly one of the first companies to work with stem cells to coax them into carrying out particular functions.

There is a rumor that Bristol-Myers may be up for spending another potential $550 million to continue iPierian's research and development, including treatments aimed at Alzheimer's. 

Bristol-Myers Squibb buys iPierian for $175 million in cash

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.